Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to inclusion into the study~* Allogeneic HSCT from HLA-identical related or unrelated donors~* Clinically confirmed acute GVHD ≥ grade II~* Age \< 70 / \> 18 years, male or female~* Karnofsky performance status \> 60 %~Exclusion Criteria:~* Oral treatment is not feasible~* Severe hepatic impairment Child-Pugh C~* Active cerebral epilepsy~* Renal failure (Creatinine clearance \< 50 ml/min)~* Life expectancy \< 3 months~* Known hypersensitivity to everolimus, sirolimus or to any of the excipients~* Confirmed pregnancy (serum β-HCG)~* Non-effective contraception for both, male and female patients, if the risk of conception exists~* Patients with limited legal capacity~* Patients unwilling and unable to undergo study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).